Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03132584 · ClinicalTrials.gov registry record · Phase 1
Cyclophosphamide and Alemtuzumab In Lymphoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03132584 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 3 participants.
The verdict
NCT03132584, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: * Cyclophosphamide * Alemtuzumab
Interventions
- DRUG Cyclophosphamide
- DRUG Alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-07-30 |
| Est. Completion | 2018-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03132584
The ClinicalTrials.gov registry entry for NCT03132584 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT03132584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03132584 about?
NCT03132584 is a clinical study titled "Cyclophosphamide and Alemtuzumab In Lymphoma". This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: * Cyclophosphamide * Alemtuzumab
What is the current status of trial NCT03132584?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-07-30. Estimated completion is 2018-01-30.
What interventions are being tested in trial NCT03132584?
The interventions under investigation include: Cyclophosphamide (DRUG), Alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT03132584?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.